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Abstract Drosophila enabled/vasodilator-stimulated phospho-
protein homology 1 (EVH1) domains are 115 residue protein^
protein interaction modules which provide essential links for their
host proteins to various signal transduction pathways. Many
EVH1-containing proteins are associated closely with actin-
based structures and are involved in re-organization of the actin
cytoskeleton. EVH1 domains are also present in proteins
enriched in neuronal tissue, thus implicating them as potential
mediators of synaptic plasticity, linking them to memory
formation and learning. Like Src homology 3, WW and GYF
domains and profilin, EVH1 domains recognize and bind specific
proline-rich sequences (PRSs). The binding is of low affinity, but
tightly regulated by the high specificity encoded into residues in
the protein:peptide interface. In general, a small (3^6 residue)
‘core’ PRS in the target protein binds a ‘recognition pocket’ on
the domain surface. Further affinity- and specificity-increasing
interactions are then formed between additional domain epitopes
and peptide ‘core-flanking’ residues. The three-dimensional
structures of EVH1:peptide complexes now reveal, in great
detail, some of the most important features of these interactions
and allow us to better understand the origins of specificity, ligand
orientation and sequence degeneracy of target peptides, in low
affinity signalling complexes. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Drosophila enabled (Ena)/vasodilator-stimulated phospho-
protein (VASP) homology 1 (EVH1) domains [1,2] are found
in a large number of multi-domain signalling proteins which
are often involved in modulating the actin cytoskeleton or in
signal transduction in postsynaptic compartments of certain
chemical synapses. Proteins containing EVH1 domains in-
clude the Ena/VASP, Wiscott-Aldrich syndrome (WASP),
RanBP1/nucleoporin and synaptic terminal protein (Homer,
Vesl) families (Fig. 1). The Ena/VASP protein family, whose
members are associated with adherens-type cell^matrix and
cell^cell junctions, micro¢laments and highly dynamic mem-
brane regions [3], is perhaps the best studied of these families
and comprises Ena, and its mammalian counterparts, Mena
(mammalian Ena), VASP, and Evl (Ena/VASP-like protein).
Mechanistically, Ena/VASP proteins are thought to enhance/
accelerate actin ¢lament formation by recruiting polymeriza-
tion competent pro¢lin^actin complexes to their proline-rich
binding partners. Recruitment of pro¢lin^actin is mediated by
GPPPPP motifs present in the central, low complexity region
of Ena/VASP proteins, whereas the highly conserved N-termi-
nal EVH1 domain mediates speci¢c binding to cytoskeleton-
associated partners containing FPPPP motifs, such as zyxin
[4], vinculin [5] and the listerial ActA protein [6], amongst
others. An additional C-terminal Ena/VASP homology 2
(EVH2) domain is required for tetramerization/oligomeriza-
tion and F-actin binding, which a¡ects indirectly the EVH1-
mediated interactions [1,7]. In contrast to the stimulatory
roles of Ena/VASP proteins in actin-based listerial motility
[8,9] and formation of membrane protrusions [10,11], increas-
ing evidence is emerging which also suggests inhibitory roles
of Ena/VASP proteins with respect to axon guidance [12,13],
cyclic nucleotide-dependent inhibition of platelet integrin
function [14,15] and inhibition of plasma membrane activity
and random motility in ¢broblasts [16].
The WASP family proteins are also closely associated with
cytoskeleton regulation and are believed to regulate actin as-
sembly downstream of Cdc42 and phosphatidylinositol 4,5-
bisphosphate signalling pathways. Their N-terminal EVH1
domains (sometimes referred to as WH1 domains) bind pro-
line-rich sequences (PRSs) in the WASP interacting protein,
which is also involved in actin re-organization. The Homer-
Vesl proteins show no obvious connection to the actin assem-
bly machinery, but are found enriched in neuronal tissue.
These proteins are proposed to play a role in long-term po-
tentiation in excitatory synapses, with implications for mem-
ory formation [17]. Homer-Vesl EVH1 domains bind selec-
tively to the C-termini of group I metabotropic glutamate
receptors (mGluRs), inositol-1,4,5-trisphosphate receptors
(IP3Rs), ryanodine receptors (RyRs) and the Shank family
proteins [18^20].
The protein^protein interactions mediated by EVH1 do-
mains are clearly highly important for the regulation of signal
transduction events, re-organization of the actin cytoskeleton,
and modulation of actin dynamics and actin-based motility.
Here, we will review the structure, function and molecular
binding characteristics of EVH1 domains in their known com-
plexes.
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2. EVH1 domains as low a⁄nity, protein^protein interaction
modules
The EVH1 domains [1,2] comprise an important family of
small, non-catalytic, protein interaction domains which specif-
ically bind target proline-rich sequences (PRSs) [4^8]. Like the
Src homology 3 domains [21,22], WW domains [23,24], GYF
domains [25,26] and pro¢lin proteins [27,28], EVH1 domains
interact with their target PRSs with remarkably low a⁄nity
(Kd values typically between 1 and 500 WM), yet nevertheless
high speci¢city [8,29]. The relevance of low a⁄nity interac-
tions in the regulation of signalling events, where large, mul-
ti-protein signalling complexes are required to form and dis-
sociate in sensitive response to external stimuli, is immediately
clear. However, more intriguing is how these interactions
maintain, at the same time, such high speci¢cities. In order
to understand the mechanisms which allow these apparently
con£icting functional properties to be satis¢ed, we need to
draw clues from the high resolution structures of these do-
mains in complex with their ligands. Combining this informa-
tion with mutational studies and other biophysical methods,
we can then go on to understand how small complementary
epitopes in both ligand and domain are used in nature to
modulate the a⁄nities of these interactions, in order to ful¢l
biological requirements.
3. EVH1 classi¢cation according to consensus PRS motifs
EVH1 domains can be divided into two classes based on the
consensus sequences of their target PRS ligands (Fig. 2). The
Ena/VASP family of proteins comprise the ¢rst class and spe-
ci¢cally recognize FPPPP-containing sequences [8]. Single res-
idue peptide substitution experiments have shown the consen-
sus binding motif for class I EVH1 domains to be FPxPP
(where P is a hydrophobic residue) [29]. Such sequences are
found in a number of mammalian proteins, including the focal
adhesion proteins zyxin and vinculin, as well as in the ActA
protein of the intracellular pathogen, Listeria monocytogenes
[4,5,8]. The complete list to date is shown in Fig. 2 (for a
recent review, see [30]). Class II EVH1 domains are found
in the Homer-Vesl protein family of postsynaptic receptor-
associated proteins [18,31]. These recognize a distinct consen-
sus PRS, with a core motif comprising PPxxF, found in the
group I mGluRs, IP3Rs, RyRs and the Shank family proteins
[19,20] (Fig. 2). The experimentally derived consensus PRS
motif recognized by class I EVH1 domains is shown in Fig.
3 (data shown are for the human VASP protein [29]). For
both VASP and Mena EVH1 domains, we showed, by sub-
stituting in turn each amino acid in the peptide target se-
quence, that proline residues at positions (31) and (2)
(FPPPP) (numbering as in Figs. 3 and 5) were essential for
EVH1 binding [29]. In contrast, the prolines at positions (0)
and (1) (FPPPP) were highly variable. Position (0) was com-
pletely non-speci¢c and could be replaced by almost any other
residue, whereas position (1) required a hydrophobic residue,
Pro, Leu, Ala, Ile, Val or Phe, in order to maintain detectable
EVH1 binding.
It has long been known that in aqueous solution, sequences
highly rich in proline spontaneously form an extended element
of secondary structure termed the left-handed PPII helix
(P=378‡, B= +146‡) shown in Fig. 3 [32,33] (for a review,
see [34]). This structure is triangular in cross section, and
generally contains proline residues in at least every third ami-
no acid position, thereby providing a hydrophobic interface of
pyrrolidine rings along one edge of the PPII prism. Although
proline usually dominates the composition of PPII helices, it is
not obligatory within this element of secondary structure. In
sequences with more than three amino acids, Val, Gln, Ser,
Arg, Ala, Thr, Asp, Glu show a high preference for PPII
structures, generally in that order [33]. In longer sequences,
the frequency of non-proline amino acids generally follows the
order: Gln, Arg, Ala, Leu, Ser, Asp, His and Glu [33]. It is
therefore no surprise that it is mostly these amino acids which
directly £ank or punctuate the proline stretches of the core
PRS motifs. In its complex with class I EVH1 domains, the
PRS motif FPPPP maintains almost perfectly the PPII helix
structure, whereas in the class II complex of Homer-1a, the
PRS ligand, TPPSPF, shows a somewhat distorted version of
this structure [35]. The di¡erences in the bound peptide geom-
etries can be rationalized in terms of the speci¢c interactions
formed with the PRS binding sites of the two classes of EVH1
domains. This provides a mechanism for speci¢c targeted rec-
ognition.
4. High resolution structures of EVH1 domains and the PRS
recognition site
The high resolution, three-dimensional structures of ¢ve
EVH1 domains from di¡erent host proteins are now known
[29,35^38]. The overall fold consists of a compact parallel
L-sandwich, closed along one edge by a long K-helix, highly
homologous to the pleckstrin homology (PH) and phospho-
tyrosine binding (PTB) domains [39]. The CK traces super-
imposed in Fig. 4 show clearly that these structures are all
almost identical, with minor di¡erences in some loop regions,
where amino acid insertions or deletions occur. The highly
conserved residues essential for hydrophobic core packing,
and therefore crucial for the correct folding of the domains,
are marked with blue bars in Fig. 1. The importance of some
of these residues in stabilizing the fold of the domain has been
C
Fig. 1. Alignment of the EVH1 domain sequences most closely related to those whose three-dimensional structures have now been determined.
Red: acidic; blue: basic; green: hydrophobic; yellow: aromatic; and purple: polar residues. Gly and Pro are shown in dark green and orange,
respectively. Red arrows highlight residues comprising the exposed aromatic cluster, which bind PRS motifs. Blue bars mark the most highly
conserved regions. GenBank accession codes from top to bottom are: BC005773 (homer3; mm/mouse), AB020879 (vesl3; rn/rat), AF093265
(homer3; hs/human), AF093262 (homer1b; hs/human), AF093257 (homer1a; mm/mouse), AF093258 (homer1b; mm/mouse), AB019479 (vesl1l ;
mm/mouse), U92079 (homer; rn/rat), AJ276327 (homer1a; rn/rat), AF093267 (homer1b; rn/rat), AF093268 (homer1c; rn/rat), AB003726 (vesl ;
rn/rat), AB007688 (vesl1l; rn/rat), AF093263 (homer2a; hs/human), AF093264 (homer2b; hs/human), AF093259 (homer2a; mm/mouse),
AF093260 (homer2b; mm/mouse), AB007689 (vesl2; rn/rat), AF093266 (homer; dm/£y), Z46389 (vasp; hs/human), AF084548 (vasp; mm/
mouse), Z46388 (vasp; cf/dog), AF112209 (evl; hs/human), U72519 (evl; mm/mouse), NM_024147 (evl; rn/rat), AB017437 (ena; av/chicken),
U72520 (mena; mm/mouse), U21123 (ena; dm/£y), AY007501 (lena; hm/leech), AB063495 (spred1; mm/mouse), AB063496 (spred2; mm/
mouse), JC5909 (ae33; dm/£y).
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veri¢ed by mutational studies [40]. The backbone root mean
square deviations (RMSDs) (calculated over all CK, N, CP
atoms) of each EVH1 domain relative to every other are sum-
marized in the table of Fig. 4. It is clear from these numbers
that the largest structural variations occur between EVH1
domains of di¡erent classes.
In all EVH1 domains, a highly conserved cluster of three,
surface-exposed aromatic sidechains (Tyr16, Trp23 and
Phe79; VASP numbering) forms the recognition site for their
target PRS ligands (Figs. 4 and 5). These positions are
marked on the alignment in Fig. 1 as red arrows. Only in
the Homer-Vesl EVH1 domains is one of these sidechains,
Tyr16, replaced by an aliphatic residue, Ile16. Invariant to
all EVH1 domains is the Trp residue at position 23 (Fig. 1),
which is not only important for ligand docking, but also
makes core hydrophobic contacts essential for correct folding.
Mutation of this Trp residue to leucine (W23L) resulted in
insoluble, inactive aggregates for which no binding constants
could be measured [29]. This observation is in agreement with
similar inactivating mutations analyzed in a yeast two-hybrid
system [41]. The Trp23 sidechain is positioned between the
Phe79 (conserved in class I and class II) and Tyr16 (the latter
conserved in the class I EVH1 domains only), and together
these form an exposed, hydrophobic ‘sticky’ platform with the
correct geometry to dock the PPII- and PPII-based structures
common to PRS ligands. The substitution of Tyr16 for Ile in
the Homer-Vesl domains implies that some very di¡erent con-
tacts are made in Homer-Vesl ‘class II’ interactions. The size
and shape of the binding cleft between Trp23 and Ile16 are
therefore modi¢ed, allowing a possible mechanism for selec-
tive binding of class II peptides (Figs. 2 and 5). Preliminary
information like this already provides interesting clues as to
the basis of speci¢city control by the di¡erent classes of EVH1
domains.
5. Structural rationalization of PRS speci¢city
To date, the structures of four EVH1 domains in complex
with PRS ligands have been solved [29,35^37]. The surface-
exposed, ligand recognition sites together with their PRS li-
gands are superimposed in Fig. 5. With this information in
hand, it is possible to rationalize some of the experimental
ligand binding data available. In both class I and class II
EVH1 domains, the conserved Phe at position 79 forms a
hydrophobic cleft between its own sidechain and that of
Trp23, angled at approximately 90‡ to each other, into which
the pyrrolidine ring of Pro(2) packs e⁄ciently (Fig. 5). In class
I domains, which bind FPxPP, a second hydrophobic cleft of
similar shape and size is created between the sidechains of
Tyr16 and Trp23, into which the Pro(31) ring packs. This
hydrophobic cleft is absent in class II EVH1 domains due
to the substitution of Tyr16 by Ile16. From inspection of
the structure of the Homer-1a EVH1 complex with the class
II peptide, TPPSPF (Fig. 5), it is clear that such a cleft would
not be so useful here, as this ligand lacks a proline sidechain
in the correct position to occupy it (i.e. position (31) in the
numbering of Fig. 5). Therefore ligand speci¢city in class II
EVH1 domains must be encoded elsewhere, perhaps in the
Phe at position (5) and in residues further removed from
the core motif, such as the C-terminal Asp residue in the
extended class II consensus sequence PPxxFxD [38]. Further
structural studies using longer peptides will be needed before
Fig. 2. Sequences of known class I and class II EVH1 target pep-
tides, located in EVH1 binding partners. The class I peptides often
occur in close tandem repeats as in zyxin and ActA. Consensus core
residues are shown in yellow and cyan and conserved core-£anking
epitopes are colored red (acidic), blue (basic) and green (hydropho-
bic). The GenBank accession codes of the EVH1 class I ligands
from top to bottom are: X69190 (zyxin, repeats 1^3; av/chicken),
X94991 (zyxin, repeats 1^4; hs/human), Y07711 (zyxin, repeats 1^4;
mm/mouse), J04126 (vinculin; av/chicken), M33308 (vinculin; hs/hu-
man), L18880 (vinculin; mm/mouse), X59723 (ActA, repeats 1^4;
lm/L. monocytogenes), NM_005578 (lpp, hs/human), AF198052 (fyb/
slap2; hs/human), AF312580 (robo3, repeats 1^2; dm/£y),
AF041053 (sax3; ceel/worm), AF279656 (sema6a1; hs/human),
AF288666 (sema6a1; mm/mouse). For the class II ligands they are:
X99675 (mGluR; dm/£y), U31215 (mGluR1K ; hs/human),
AF320126 (mGluR1; mm/mouse), NM_017011 (mGluR; rn/rat),
D10891 (mGluR5; rn/rat), D26070 (IP3R1; hs/human), AF157625
(IP3R1; bov/cow), J05510 (IP3R; rn/rat), D14400 (IP3R; xel/frog),
AJ238949 (IP3R; dm/£y), AF168688 (IP3R; ceel/worm), J05200
(RyR; hs/human), X15750 (RyR; oc/rabbit), M91452 (RyR; ss/pig),
AF131951 (shank1a; rn/rat), AF133301 (shank3, repeats 1^2; rn/
rat).
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the origin of speci¢city in class II interactions can be fully
understood.
The close packing interactions of Pro(31) and Pro(2) of the
peptide core motif (FPPPP) into the class I EVH1 surfaces
explain their strict conservation in all Ena/VASP binding pep-
tides (Figs. 2 and 3). The variability of the two central pro-
lines in class I ligands can also be explained by the structures
of the complexes: Pro(0) is oriented such that its sidechain
makes no contact with the domain surface, thus allowing a
wide variety of sidechains at this position; and Pro(1) makes
very few contacts, resulting in only the more general require-
ment for a hydrophobic residue at position (1). In Homer
complex with TPPSPF, the pattern of strictly conserved and
unconserved peptide residues can be similarly rationalized.
The Ser(3), Pro(4) residues induce a type VIa L-turn which
modi¢es the PPII helix geometry so that the ligand twists
away from the surface of the domain [35]. The sidechains of
Ser(3) and Pro(4) are therefore, not surprisingly, divergent
between the various ligands of the di¡erent Homer proteins.
In class II interactions, Pro(31) is replaced by a di¡erent
sidechain, but in most cases, one of a hydrophobic nature
which could then pack into the alternatively shaped hydro-
phobic cleft formed between Trp24 and Ile16 (Homer-1a
numbering; see Fig. 5).
Another important feature of EVH1^PRS interactions is
the conservation of a hydrogen bond between the indole
NH of Trp23 and the carbonyl oxygen of the ligand Pro(0)
(Fig. 5). A second, conserved hydrogen bond between Gln81
and the carbonyl oxygen of the peptide Pro(31) is also seen in
all of the class I EVH1 complexes, and based on the structural
Fig. 3. Left: the PPII left-handed helix structure [32,33], showing the triangular cross section and the view along the length of the chain. It can
be seen clearly that every third proline aligns along the same face, as illustrated here for Pro(31) and Pro(2). Right: single residue substitution
analysis of the EVH1 binding PRS peptide ‘SFEFPPPPTEDEL’ from the third ActA PRS repeat (ActA residues 332^344). Peptide residues
were substituted in turn for all natural amino acid alternatives (rows) and assayed for binding to the VASP EVH1 domain [29]. The far left
column is a control, showing the binding of the wild-type sequence. Spot intensities re£ect the EVH1 binding a⁄nities of each peptide mea-
sured. The FPPPP core sequence is enclosed by the red box and the C-terminal ‘EL’ epitope, responsible for increasing EVH1 binding a⁄nity,
is enclosed by a dashed red box. Yellow arrows mark the conserved prolines.
Fig. 4. Superposition of the backbone (N, CK, and CP) atoms of the ¢ve EVH1 domains for which high resolution structures are now avail-
able: Mena (cyan), Evl (green), VASP (magenta), Homer-1a (yellow) and Vesl-2 (red) [29,35^38]. The residues of the aromatic triad, Tyr16,
Trp23, Phe79 (VASP numbering), are shown in blue. Backbone (CK, CP, N) RMSDs (Aî ) of each EVH1 structure relative to all others are sum-
marized in the table. The classi¢cation into class I and class II domains is also given.
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information examined so far, it is tempting to predict that this
interaction should also be present in class II interactions.
However, this hydrogen bond was not detected in the Homer
complex and the peptide ligand studied in this case would
need to be extended by at least one additional N-terminal
amino acid to test this hypothesis. That both of these hydro-
gen bonds play important roles in ligand docking can be seen
not only from their degree of conservation, but also experi-
mentally, from the very large perturbations in both 15N and
1H chemical shifts of the donor Trp23 NH and Gln81 NH2
atoms observed in nuclear magnetic resonance measurements
carried out on the VASP EVH1 domain [29].
6. Ligand orientation, speci¢city and a⁄nity regulation: the
role of core-£anking residues
Flanking the core PRS motifs of all EVH1 ligands are
residues or groups of residues comprising epitopes which
modify interaction a⁄nities, and as a result modulate specif-
icity. Some of these residues are positioned directly next to the
proline-rich region and constitute part of the actual consensus
recognition motif, whereas other epitopes are several amino
acids removed from the core. It is the interactions with the
former class of epitopes which largely determine the binding
orientation for otherwise highly symmetrical PRS peptide li-
gands. For example, the Ena/VASP EVH1 domains target
very speci¢cally, PRSs directly preceded by a single Phe res-
idue (at the ligand (32) position), which gives the ligand an
unambiguous directionality. Phe(32) is responsible for setting
the register of binding in this class of EVH1 domains, ensur-
ing that only Pro(31) and Pro(2), and not the other prolines
in the peptide, dock into the available clefts. Mutation of
Phe(32) to any amino acid, with the exception of Trp, results
in loss of binding to EVH1 [8,29]. From the three known class
I complex structures, we can see that the sidechain of Phe(32)
packs neatly into the peptide binding groove of the EVH1
domain [29,36,37]. However, docking experiments using mo-
lecular dynamics simulations have also suggested a possibility
that FPPPP-containing ligands could bind in the opposite
orientation, with Phe(32) packing, albeit less e⁄ciently, into
an alternative hydrophobic site at the opposite end of this
groove (Ball et al., unpublished results). There is therefore
some scope for the possibility of forward and reverse binding
modes in EVH1 domains. In Fig. 3, one can see that weak
EVH1 binding occurs when a Phe (or Trp) residue replaces
Pro(2). This could suggest that a small fraction of the peptide
binds in the opposite orientation. However, if this was the
case, one would also expect to see a corresponding faint
spot in the column where Pro replaces Phe(32), and no
such spot is visible. It therefore seems more likely that the
EVH1 domain is binding the mutant sequence, FPPPF (or
FPPPW), than binding the FPPPP sequence in reverse. It
might also be expected from the apparently reversed sequence
of the Homer-1a target PRS, TPPSPF, that class II EVH1
domains should bind their peptides in the opposite orientation
to the class I domains. Somewhat surprisingly, however, this
is not the case and the TPPSPF peptide of Homer was shown
to bind the Homer EVH1 domain with the same orientation
as the Ena/VASP EVH1 domains [35]. Thus, although molec-
ular dynamics simulations show that reverse polarity binding
of EVH1 peptides is not sterically forbidden, there is to date
no example of this. Interestingly, the class II peptide of the
Human RyR di¡ers from other class II peptides in its distri-
bution of core-£anking basic and hydrophobic residues, which
may have implications for reverse polarity binding. Whether
EVH1 domains do indeed possess dual polarity peptide bind-
ing modes, however, remains to be con¢rmed experimentally.
Although orientation and speci¢city are partly controlled
by the core motif, the binding a⁄nities of isolated, short
core peptides to EVH1 domains range from very weak to
Fig. 5. Superposition (shown in stereoview) of the exposed, PRS^ligand recognition sites from the structures of the four known EVH1^PRS
complexes (Mena, Evl, VASP and Homer-1a) [29,35^37]. The most important sidechains involved in the protein^ligand interaction are rendered
in bold. The Ena/VASP (class I) peptides are shown in yellow and the Homer (class II) peptide is shown, and numbered, in green. It is clear
that Pro(2) plays a crucial role in both classes of EVH1 interaction and that Pro(31) is extremely important in the Ena/VASP class I interac-
tions. In class I interactions, both Pro(31) and Pro(2) sidechains pack very e⁄ciently into the hydrophobic clefts created by the exposed Tyr,
Trp, Phe triads on surfaces of class I EVH1 domains. In class II interactions, Pro(31) is replaced by a di¡erent sidechain, but usually of a hy-
drophobic nature, which could then pack into the di¡erently shaped hydrophobic pocket formed in class II EVH1 surfaces where Tyr16 is re-
placed by Ile16 (colored in pink). Also shown is the conserved position of Gln81, which contributes to peptide binding via hydrogen bond for-
mation [29]. Numbering of the PRS ligands is based on de¢ning position (0) as the ¢rst position common to both ligands in these complexes.
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undetectable. Further interactions are therefore needed to in-
crease the a⁄nities to appropriate levels. The modulation of
binding a⁄nity is largely under the control of epitopes a few
amino acids further removed from the PRS core motif itself.
These form either hydrophobic, hydrogen-bonded or electro-
static interactions with the domain surface. The hydrophobic
surfaces of the EVH1 domains contain several small, addi-
tional hydrophobic patches close to the PPII binding groove
[29]. One example is the area consisting of residues Gln31 to
Phe33 in the Ena/VASP family (VASP numbering), which
interacts with a conserved, a⁄nity-raising EL epitope found
C-terminal to each of the four FPPPP repeats in listerial ActA
[29]. Because this epitope is absent in the endogenous Ena/
VASP EVH1 binding partners, such as zyxin and vinculin (see
Fig. 2), it is thought that the pathogen exploits the smaller,
second hydrophobic EVH1 surface in order to increase its
own binding a⁄nity for EVH1 over that of the competing,
native, zyxin/vinculin FPPPP-containing ligands [29]. In this
way the ActA protein enables Listeria to successfully recruit
EVH1-containing proteins for the synthesis of actin comet
tails which provide the pathogen with the intracellular motil-
ity required for infection of neighboring cells. It has also been
shown that acidic to basic mutations in the £anking residues
of the second ActA FPPPP repeat severely reduce binding to
the VASP EVH1 domain. However, binding was shown to be
partially rescued (V3% binding regained) by complementary
charge mutations on the EVH1 domain surface [41].
7. Conclusions
Combining structural information with biochemical meth-
ods, we can see that relatively minor structural variations on
the EVH1 domain surfaces, together with corresponding com-
plementary variations in their ligands can provide mechanisms
for selectivity in PRS recognition. Importantly, such mecha-
nisms do not exclude the possibility of overlapping peptide
recognition, so that class I domains may well be able to
bind to class II ligands and vice versa, albeit with reduced
a⁄nities. This allows the possibility for one EVH1-containing
protein to rescue, at least to some extent, the e¡ects of knock-
ing out another, as observed experimentally [16,30,40,42].
This, in some cases, may prove highly valuable to the host
cell. The available data suggest that EVH1 domains evolved
from the versatile PH/PTB folding sca¡old, and then diverged
to ful¢l specialized and partially overlapping functions in dif-
ferent cellular contexts, whilst maintaining the common abil-
ity to bind PRSs.
The high resolution structural information now available
clari¢es our understanding of the most important features of
EVH1-mediated interactions and of the subtle factors which
govern target speci¢city and binding a⁄nity. This information
can be used to facilitate the design of novel peptide, non-
peptide and small organic molecule inhibitors which interfere
with the binding of EVH1-containing proteins to their respec-
tive partners. Such rationally designed inhibitors would be
useful in several ways. Firstly, and perhaps most importantly,
highly selective EVH1 inhibitors would provide invaluable
tools for the dissection of biochemical pathways, which could
be used in a dose-dependent manner, to directly complement
data from corresponding genetic knockout models. Secondly,
appropriately modi¢ed EVH1 ligands would also ¢nd uses as
molecular tags to monitor the formation and dissociation of
EVH1-mediated interactions within the cell. And thirdly, such
inhibitors may ultimately provide the precursors/lead mole-
cules needed for the development of future generations of
novel therapeutics, which could help in the treatment of dis-
eases in which controlled or partial inhibition of EVH1-medi-
ated events would be desirable (for example, the spreading of
intracellular pathogens, pathologically altered adhesion and
motility in in£ammatory and metastatic diseases). All of these
possibilities provide a great number of fascinating and chal-
lenging tasks for the future.
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